### Vinorelbine

**Indication**
- Other specified malignant neoplasms of bronchus or lung (ICD11 code: 2C75.Y)

**INN**
- Vinorelbine

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
  - Read more [about patents](#).

**Tags**
- Cancer

**Wikipedia**
- [Vinorelbine](#)

**DrugBank**
- [Vinorelbine](#)

---

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of vinorelbine 80 mg capsules from the EMLc, and modification of the description of the parenteral forms on the EML and EMLc to 10 mg/mL in 1 mL and 5 mL vials.

[Expert Committee report](#)